255 related articles for article (PubMed ID: 31255193)
1. Decision Making in Indeterminate Thyroid Nodules and the Role of Molecular Testing.
Mitchell J; Yip L
Surg Clin North Am; 2019 Aug; 99(4):587-598. PubMed ID: 31255193
[TBL] [Abstract][Full Text] [Related]
2. A 10-Gene Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study.
González HE; Martínez JR; Vargas-Salas S; Solar A; Veliz L; Cruz F; Arias T; Loyola S; Horvath E; Tala H; Traipe E; Meneses M; Marín L; Wohllk N; Diaz RE; Véliz J; Pineda P; Arroyo P; Mena N; Bracamonte M; Miranda G; Bruce E; Urra S
Thyroid; 2017 Aug; 27(8):1058-1067. PubMed ID: 28521616
[TBL] [Abstract][Full Text] [Related]
3. Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations.
Keutgen XM; Filicori F; Fahey TJ
Expert Rev Mol Diagn; 2013 Jul; 13(6):613-23. PubMed ID: 23895130
[TBL] [Abstract][Full Text] [Related]
4. Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment.
Yip L; Sosa JA
JAMA Surg; 2016 Jul; 151(7):663-70. PubMed ID: 27223483
[TBL] [Abstract][Full Text] [Related]
5. Overview of molecular biomarkers for enhancing the management of cytologically indeterminate thyroid nodules and thyroid cancer.
Duick DS
Endocr Pract; 2012; 18(4):611-5. PubMed ID: 22849877
[TBL] [Abstract][Full Text] [Related]
6. An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer.
Nicholson KJ; Yip L
Curr Opin Oncol; 2018 Jan; 30(1):8-15. PubMed ID: 29028645
[TBL] [Abstract][Full Text] [Related]
7. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
Patel KN; Angell TE; Babiarz J; Barth NM; Blevins T; Duh QY; Ghossein RA; Harrell RM; Huang J; Kennedy GC; Kim SY; Kloos RT; LiVolsi VA; Randolph GW; Sadow PM; Shanik MH; Sosa JA; Traweek ST; Walsh PS; Whitney D; Yeh MW; Ladenson PW
JAMA Surg; 2018 Sep; 153(9):817-824. PubMed ID: 29799911
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical Subcellular Localization of Protein Biomarkers Distinguishes Benign from Malignant Thyroid Nodules: Potential for Fine-Needle Aspiration Biopsy Clinical Application.
Ralhan R; Veyhl J; Chaker S; Assi J; Alyass A; Jeganathan A; Somasundaram RT; MacMillan C; Freeman J; Vescan AD; Witterick IJ; Walfish PG
Thyroid; 2015 Nov; 25(11):1224-34. PubMed ID: 26131603
[TBL] [Abstract][Full Text] [Related]
9. Getting more out of molecular testing for indeterminate thyroid nodules.
Angell TE
Cancer Cytopathol; 2019 Sep; 127(9):555-556. PubMed ID: 31237737
[No Abstract] [Full Text] [Related]
10. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
11. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
12. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnostic testing and the indeterminate thyroid nodule.
Yip L
Curr Opin Oncol; 2014 Jan; 26(1):8-13. PubMed ID: 24225416
[TBL] [Abstract][Full Text] [Related]
14. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
[TBL] [Abstract][Full Text] [Related]
15. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
16. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
Bose S; Sacks W; Walts AE
Adv Anat Pathol; 2019 Mar; 26(2):114-123. PubMed ID: 30664001
[TBL] [Abstract][Full Text] [Related]
17. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
[TBL] [Abstract][Full Text] [Related]
18. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic usefulness of tumor markers in the thyroid cytological samples extracted by fine-needle aspiration biopsy.
Gómez Sáez JM
Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):47-56. PubMed ID: 20088814
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Sequencing Identifies a Highly Accurate miRNA Panel That Distinguishes Well-Differentiated Thyroid Cancer from Benign Thyroid Nodules.
Mazeh H; Deutch T; Karas A; Bogardus KA; Mizrahi I; Gur-Wahnon D; Ben-Dov IZ
Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):858-863. PubMed ID: 30049841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
